Drug intelligence / Profile preview

EQL-988

Development stage: Preclinical
Lead developer: EQUULUS Therapeutics
Modality: Small Molecules
Administration: Intranasal

Overview

EQL-988 is a small molecule agonist of the thyrotropin-releasing hormone (TRH) receptor, currently under development by EQUULUS Therapeutics. It is specifically designed as an intranasal formulation to facilitate direct delivery to the central nervous system, bypassing the blood-brain barrier. The drug is being developed for the treatment of suicidality in patients with depression. By activating TRH receptors, EQL-988 aims to modulate neurobiological pathways associated with mood regulation and suicidal ideation. The program is currently in the preclinical stage, with Phase I clinical trials as the next anticipated milestone.

Targets

TRHR (Thyrotropin-releasing hormone receptor)

Beyond the preview

Go deeper on EQL-988.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EQL-988.

Explore the full profile